Abstract:
:Global remodeling of the chromatin landscape occurs during senescence, although its functional consequence is still unclear. In this issue, Tasdemir and colleagues show that the epigenetic regulator BRD4 is required for expression of the proinflammatory senescence-associated secretory phenotype and immune clearance of senescent cells in vitro and in vivo Their results could be useful in the design of novel therapies to treat aging-related diseases, including cancer.Cancer Discov; 6(6); 576-8. ©2016 AACR.See related article by Tasdemir et al., p. 612.
journal_name
Cancer Discovjournal_title
Cancer discoveryauthors
Vizioli MG,Adams PDdoi
10.1158/2159-8290.CD-16-0485subject
Has Abstractpub_date
2016-06-01 00:00:00pages
576-8issue
6eissn
2159-8274issn
2159-8290pii
6/6/576journal_volume
6pub_type
评论,杂志文章相关文献
Cancer Discovery文献大全abstract::HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...
journal_title:Cancer discovery
pub_type: 评论,信件
doi:10.1158/2159-8290.CD-RW2016-052
更新日期:2016-05-01 00:00:00
abstract::Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant. Howe...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-NB2019-061
更新日期:2019-07-01 00:00:00
abstract::A recent study suggests that natural killer (NK) cells may play an important role in antitumor response to immune checkpoint inhibitors. Researchers used mouse models to show that NK cells respond to PD-1 and PD-L1 inhibitors, information that could be used to develop immunotherapies that tap NK cells to combat cancer...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-NB2018-131
更新日期:2018-12-01 00:00:00
abstract::MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-RW2020-178
更新日期:2020-12-11 00:00:00
abstract::MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arisin...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-19-0620
更新日期:2020-06-01 00:00:00
abstract:UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-13-0830
更新日期:2014-10-01 00:00:00
abstract::In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly occurs, and ex vivo models support that some of these bacteria can trigger host transcriptomic signatures associated with carcinogenesis. Here, we show that this lower airway dysbiotic signature was more prevalent in the stage IIIB...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-20-0263
更新日期:2020-11-11 00:00:00
abstract::E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-11-0104
更新日期:2011-09-01 00:00:00
abstract::In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. Ho...
journal_title:Cancer discovery
pub_type: 临床试验,杂志文章
doi:10.1158/2159-8290.CD-NB2017-087
更新日期:2017-08-01 00:00:00
abstract::To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-19-0125
更新日期:2019-07-01 00:00:00
abstract::53BP1 integrates pRB activity with the DNA damage response by binding to methylated K810. ...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-RW2014-164
更新日期:2014-09-01 00:00:00
abstract:UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-11-0124
更新日期:2011-11-01 00:00:00
abstract:UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-15-0235
更新日期:2015-11-01 00:00:00
abstract::The pks+E. coli metabolite colibactin caused a unique mutational signature in intestinal organoids. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-RW2020-037
更新日期:2020-05-01 00:00:00
abstract::Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. ...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-NB2018-084
更新日期:2018-08-01 00:00:00
abstract:: Farge and colleagues describe a novel in vivo approach to identify and study primary acute myeloid leukemia (AML) cells that persist in the marrow after chemotherapy. They discovered that AML cells that persist in the mouse marrow after treatment with cytarabine have increased oxidative phosphorylation and that i...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-17-0476
更新日期:2017-07-01 00:00:00
abstract::The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Two reports in this issue of Cancer Discovery uncover additional mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment. These findings...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-12-0387
更新日期:2012-10-01 00:00:00
abstract:UNLABELLED:CD96 has recently been shown as a negative regulator of mouse natural killer (NK)-cell activity, with Cd96(-/-)mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-15-0944
更新日期:2016-04-01 00:00:00
abstract::A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2015-149
更新日期:2015-12-01 00:00:00
abstract::Three genetic markers performed far better than histologic criteria to classify diffuse low-grade gliomas, laying the foundation for molecular diagnosis of this heterogeneous group of brain tumors. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2015-092
更新日期:2015-08-01 00:00:00
abstract::MET is critical for antitumor neutrophil infiltration to HGF-secreting tumors and inflammatory sites. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-RW2015-097
更新日期:2015-07-01 00:00:00
abstract::A report from the American Cancer Society reveals that colorectal cancer in people younger than 50 continues to increase, a trend that has spread to the 50-to-64 age group for the first time. Multiple lines of evidence indicate that obesity, often pinpointed as the cause, is not the only contributor. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2020-016
更新日期:2020-06-01 00:00:00
abstract::In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2020-013
更新日期:2020-05-01 00:00:00
abstract::Margetuximab outperformed trastuzumab in a phase III, head-to-head trial of the two anti-HER2 agents among patients with HER2-positive metastatic breast cancer. The new antibody drug was engineered for enhanced immune activity against HER2-expressing tumor cells. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2019-069
更新日期:2019-08-01 00:00:00
abstract:: In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sens...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-17-0860
更新日期:2017-10-01 00:00:00
abstract::Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provi...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-14-0410
更新日期:2014-06-01 00:00:00
abstract::Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/ref...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2017-088
更新日期:2017-08-01 00:00:00
abstract::With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we e...
journal_title:Cancer discovery
pub_type: 杂志文章,评审
doi:10.1158/2159-8290.CD-18-1196
更新日期:2019-05-01 00:00:00
abstract::Ionizing irradiation and PD-L1 blockade synergistically enhance antitumor immunity. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-RW2014-012
更新日期:2014-03-01 00:00:00
abstract:UNLABELLED:Although disordered chromatin organization has long been recognized as a feature of cancer, the molecular underpinnings of chromatin structure, epigenetic regulation, and their relationships to transcription are only beginning to be understood. Cancer genome sequencing studies have revealed a novel theme: fr...
journal_title:Cancer discovery
pub_type: 杂志文章,评审
doi:10.1158/2159-8290.CD-12-0361
更新日期:2013-01-01 00:00:00